Revefenacin: Difference between revisions
Jump to navigation
Jump to search
Line 33: | Line 33: | ||
==Pharmacology== | ==Pharmacology== | ||
See Clinical | See Clinical Studies | ||
==Clinical Studies== | ==Clinical Studies== |
Revision as of 03:52, 8 October 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Uma Maveli[2]
Overview
Adult Indications and Dosage
- The agreed dosage is 175 micrograms per day
- Taken via a standard jet nebulizer (turns liquid medication into mist) connected to an air compressor
- Makes it easy for patients with pulmonary problems
Pediatric Indications and Dosage
Contradictions
Warnings
Adverse Reactions
Side Effects
- Headache
- Cough
- Problems regarding the upper respiratory system
- Back Pain
Drug Interactions
Use in Specific Populations
IV Compatibility
- Intravenous solution in healthy volunteers
- Volume of distribution was 218 L
- Intravenous solution radioactivity:
- 54% came out as solid waste
- 27% came out as liquid waste
Pharmacology
See Clinical Studies
Clinical Studies
Trials:
- Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD
- 88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better)
How is it supplied
- Given to patients via jet nebulizer
Patient Counseling Information
Precautions with Alcohol
Brand Names
- Yupelri